INTERVENTION 1:	Intervention	0
Cisplatin and Cetuximab	Intervention	1
cisplatin	CHEBI:27899	0-9
Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly. Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab only until progressive disease (PD) or occurrence of unacceptable toxicity.	Intervention	2
cisplatin	CHEBI:27899	0-9
cisplatin	CHEBI:27899	299-308
meter	UO:0000008	34-39
day	UO:0000033	91-94
stable	HP:0031915	261-267
disease	DOID:4,OGMS:0000031	268-275
disease	DOID:4,OGMS:0000031	367-374
progressive	HP:0003676	355-366
INTERVENTION 2:	Intervention	3
Cisplatin	Intervention	4
cisplatin	CHEBI:27899	0-9
Cisplatin 75 mg/m^2 IV infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles until the first occurrence of PD, unacceptable toxicity or withdrawal of consent.	Intervention	5
cisplatin	CHEBI:27899	0-9
day	UO:0000033	48-51
Inclusion Criteria:	Eligibility	0
Histologically confirmed diagnosis of metastatic breast cancer (Stage IV)	Eligibility	1
breast cancer	DOID:1612	49-62
Estrogen Receptor [ER] negative, PgR negative and HER2 less than 3+ expression by immunohistochemistry (IHC)	Eligibility	2
estrogen	CHEBI:50114,BAO:0000760	0-8
receptor	BAO:0000281	9-17
immunohistochemistry	BAO:0000415	82-102
No more than 1 prior chemotherapy received for treating this metastatic breast cancer	Eligibility	3
breast cancer	DOID:1612	72-85
No more than 1 prior anthracycline and/or taxane regimen (either adjuvant or metastatic setting)	Eligibility	4
anthracycline	CHEBI:48120	21-34
taxane	CHEBI:36064	42-48
adjuvant	CHEBI:60809	65-73
Other protocol-defined inclusion criteria may apply	Eligibility	5
Exclusion Criteria:	Eligibility	6
Prior platinum agent	Eligibility	7
platinum	CHEBI:33364	6-14
Prior mitomycin	Eligibility	8
mitomycin	CHEBI:25357	6-15
Known history of brain metastases	Eligibility	9
history	BFO:0000182	6-13
brain	UBERON:0000955	17-22
Other protocol-defined exclusion criteria may apply	Eligibility	10
Outcome Measurement:	Results	0
Best Overall Response (BOR)	Results	1
Percentage of participants with best overall (objective) response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).	Results	2
Time frame: Evaluations were performed every 6 weeks until progression reported between day of first participant randomized, 20 June 2007, until cut-off date, 31 July 2009	Results	3
time	PATO:0000165	0-4
day	UO:0000033	88-91
Results 1:	Results	4
Arm/Group Title: Cisplatin and Cetuximab	Results	5
cisplatin	CHEBI:27899	17-26
Arm/Group Description: Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly. Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab only until progressive disease (PD) or occurrence of unacceptable toxicity.	Results	6
cisplatin	CHEBI:27899	23-32
cisplatin	CHEBI:27899	322-331
meter	UO:0000008	57-62
day	UO:0000033	114-117
stable	HP:0031915	284-290
disease	DOID:4,OGMS:0000031	291-298
disease	DOID:4,OGMS:0000031	390-397
progressive	HP:0003676	378-389
Overall Number of Participants Analyzed: 115	Results	7
Measure Type: Number	Results	8
Unit of Measure: percentage of participants  20.0        (13.1 to 28.5)	Results	9
Results 2:	Results	10
Arm/Group Title: Cisplatin	Results	11
cisplatin	CHEBI:27899	17-26
Arm/Group Description: Cisplatin 75 mg/m^2 IV infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles until the first occurrence of PD, unacceptable toxicity or withdrawal of consent.	Results	12
cisplatin	CHEBI:27899	23-32
day	UO:0000033	71-74
Overall Number of Participants Analyzed: 58	Results	13
Measure Type: Number	Results	14
Unit of Measure: percentage of participants  10.3        (3.9 to 21.2)	Results	15
Adverse Events 1:	Adverse Events	0
Total: 41/114 (35.96%)	Adverse Events	1
Anaemia * 3/114 (2.63%)	Adverse Events	2
Leukopenia * 1/114 (0.88%)	Adverse Events	3
leukopenia	HP:0001882,DOID:615	0-10
Thrombocytopenia * 1/114 (0.88%)	Adverse Events	4
thrombocytopenia	HP:0001873,DOID:1588	0-16
Tachycardia * 0/114 (0.00%)	Adverse Events	5
tachycardia	HP:0001649	0-11
Abdominal Distention * 1/114 (0.88%)	Adverse Events	6
abdominal distention	HP:0003270	0-20
Abdomial Pain * 1/114 (0.88%)	Adverse Events	7
pain	HP:0012531	9-13
Diarrhoea * 3/114 (2.63%)	Adverse Events	8
Intestinal Obstruction * 0/114 (0.00%)	Adverse Events	9
intestinal obstruction	HP:0005214,DOID:8437	0-22
Melaena * 1/114 (0.88%)	Adverse Events	10
Nausea * 2/114 (1.75%)	Adverse Events	11
nausea	HP:0002018	0-6
Vomiting * 1/114 (0.88%)	Adverse Events	12
vomiting	HP:0002013	0-8
Asthenia * 2/114 (1.75%)	Adverse Events	13
asthenia	HP:0025406	0-8
Adverse Events 2:	Adverse Events	14
Total: 13/57 (22.81%)	Adverse Events	15
Anaemia * 0/57 (0.00%)	Adverse Events	16
Leukopenia * 0/57 (0.00%)	Adverse Events	17
leukopenia	HP:0001882,DOID:615	0-10
Thrombocytopenia * 0/57 (0.00%)	Adverse Events	18
thrombocytopenia	HP:0001873,DOID:1588	0-16
Tachycardia * 1/57 (1.75%)	Adverse Events	19
tachycardia	HP:0001649	0-11
Abdominal Distention * 0/57 (0.00%)	Adverse Events	20
abdominal distention	HP:0003270	0-20
Abdomial Pain * 0/57 (0.00%)	Adverse Events	21
pain	HP:0012531	9-13
Diarrhoea * 0/57 (0.00%)	Adverse Events	22
Intestinal Obstruction * 1/57 (1.75%)	Adverse Events	23
intestinal obstruction	HP:0005214,DOID:8437	0-22
Melaena * 0/57 (0.00%)	Adverse Events	24
Nausea * 0/57 (0.00%)	Adverse Events	25
nausea	HP:0002018	0-6
Vomiting * 1/57 (1.75%)	Adverse Events	26
vomiting	HP:0002013	0-8
Asthenia * 0/57 (0.00%)	Adverse Events	27
asthenia	HP:0025406	0-8
